摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-methyl-5-phenyl-2-propylpyrimidin-4(3H)-one | 1028743-03-4

中文名称
——
中文别名
——
英文名称
6-methyl-5-phenyl-2-propylpyrimidin-4(3H)-one
英文别名
4-methyl-5-phenyl-2-propyl-1H-pyrimidin-6-one
6-methyl-5-phenyl-2-propylpyrimidin-4(3H)-one化学式
CAS
1028743-03-4
化学式
C14H16N2O
mdl
——
分子量
228.294
InChiKey
PLJDULANVNHJOJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    17
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    41.5
  • 氢给体数:
    1
  • 氢受体数:
    1

反应信息

  • 作为反应物:
    描述:
    6-methyl-5-phenyl-2-propylpyrimidin-4(3H)-one2-氰基-4'-溴甲基联苯sodium;hydride乙酸乙酯乙酸乙酯 、 Brine 、 magnesium sulfate 、 silica gel 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 3.0h, 以to give the title compound as a pale-yellow viscous substance (0.30 g, 62%)的产率得到4'-[(4-methyl-6-oxo-5-phenyl-2-propylpyrimidin-1(6H)-yl)methyl]biphenyl-2-carbonitrile
    参考文献:
    名称:
    HETEROMONOCYCLIC COMPOUND AND USE THEREOF
    摘要:
    一种化合物由式(I)表示,其中R1为氧代基、═N—R或类似基团;式中的基团为:其中R2为式中表示的基团;R3和R4各自为H、C1-C6烷基、C3-C6环烷基、C1-C6烷氧基、C1-C6烷基氨基、二(C1-C6)烷基氨基或C1-C6烷基硫基,每个基团均可选择性地被取代;而R5为H、C1-C6烷基、C2-C6烯基、环状基团,每个基团均可选择性地被取代,或为—CO—R8或—O—R8′;或其盐。本发明的化合物可用作预防或治疗心血管疾病、代谢性疾病和/或中枢神经系统疾病的药物。
    公开号:
    US20110112120A9
  • 作为产物:
    描述:
    在 ammonium acetate 作用下, 以 溶剂黄146 为溶剂, 反应 0.25h, 生成 6-methyl-5-phenyl-2-propylpyrimidin-4(3H)-one
    参考文献:
    名称:
    A facile synthesis of pyrimidin-4-ones
    摘要:
    A facile synthesis of 2,6-disubstituted pyrimidin-4-ones and 2,5,6-trisubstituted pyrimidin-4-ones from commercially available materials with application of microwave technology in key steps is described. (C) 2009 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.tetlet.2009.11.096
点击查看最新优质反应信息

文献信息

  • HETEROMONOCYCLIC COMPOUND AND USE THEREOF
    申请人:Kuroita Takanobu
    公开号:US20080207654A1
    公开(公告)日:2008-08-28
    A compound represented by the formula (I): wherein R1 is an oxo group, ═N—R or the like; a group represented by the formula: is a group represented by the formula: R2 is a group represented by the formula: R3 and R4 are each H, or C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkylamino, di(C1-C6)alkylamino or C1-C6 alkylthio, each of which is optionally substituted; and R5 is H, or C1-C6 alkyl, C2-C6 alkenyl, cyclic group, each of which is optionally substituted, —CO—R8 or —O—R8′, or a salt thereof. The compound of the present invention is useful as a drug for the prophylaxis or treatment of circulatory diseases, metabolic diseases and/or central nervous system diseases.
    化合物的化学式为(I),其中R1为氧代基,═N—R或类似基团;式中的基团表示为:其中R2为式中的基团;R3和R4分别为H,或C1-C6烷基,C3-C6环烷基,C1-C6烷氧基,C1-C6烷基氨基,二(C1-C6)烷基氨基或C1-C6烷基硫基,每个基团均可选地被取代;R5为H,或C1-C6烷基,C2-C6烯基,环状基团,每个基团均可选地被取代,—CO—R8或—O—R8′,或其盐。本发明的化合物可用作预防或治疗循环系统疾病、代谢性疾病和/或中枢神经系统疾病的药物。
  • Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases
    申请人:Takeda Pharmaceutical Company Limited
    公开号:US07803940B2
    公开(公告)日:2010-09-28
    A compound represented by the formula (I): wherein R1 is an oxo group, ═N—R or the like; a group represented by the formula: is a group represented by the formula: R2 is a group represented by the formula: R3 and R4 are each H, or C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkylamino, di(C1-C6)alkylamino or C1-C6 alkylthio, each of which is optionally substituted; and R5 is H, or C1-C6 alkyl, C2-C6 alkenyl, cyclic group, each of which is optionally substituted, —CO—R8 or —O—R8′, or a salt thereof. The compound of the present invention is useful as a drug for the prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases.
    化合物的化学式为(I),其中R1代表氧代基,═N—R或类似基团;式中代表的基团为:R2代表式中代表的基团;R3和R4分别代表氢、C1-C6烷基、C3-C6环烷基、C1-C6烷氧基、C1-C6烷基氨基、双(C1-C6)烷基氨基或C1-C6烷基硫基,每个基团都可以选择性地被取代;R5代表氢、C1-C6烷基、C2-C6烯基、环状基团,每个基团都可以选择性地被取代,—CO—R8或—O—R8′,或其盐。本发明的化合物可用作预防或治疗心血管疾病、代谢性疾病和/或中枢神经系统疾病的药物。
  • Heteromonocyclic compound and use thereof
    申请人:Takeda Pharmaceutical Company Limited
    公开号:EP2256115A1
    公开(公告)日:2010-12-01
    A compound represented by the formula (I): wherein R1 is an oxo group, =N-R or the like; a group represented by the formula: is a group represented by the formula: R2 is a group represented by the formula: R3 and R4 are each H, or C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkylamino, di(C1-C6)alkylamino or C1-C6 alkylthio, each of which is optionally substituted; and R5 is H, or C1-C6 alkyl, C2-C6 alkenyl, cyclic group, each of which is optionally substituted, -CO-R8 or -O-R8', or a salt thereof. The compound of the present invention is useful as a drug for the prophylaxis or treatment of circulatory diseases, metabolic diseases and/or central nervous system diseases.
    式 (I) 所代表的化合物: 其中 R1 是氧代基团、=N-R 或类似基团;由式(I)代表的基团: 是由式(I)代表的基团 R2 是由式......表示的基团: R3和R4各自为H,或C1-C6烷基、C3-C6环烷基、C1-C6烷氧基、C1-C6烷基氨基、二(C1-C6)烷基氨基或C1-C6烷硫基,其中每个基团任选被取代;R5为H,或C1-C6烷基、C2-C6烯基、环状基团,其中每个基团任选被取代,-CO-R8或-O-R8',或其盐。本发明的化合物可用作预防或治疗循环系统疾病、代谢疾病和/或中枢神经系统疾病的药物。
  • US7803940B2
    申请人:——
    公开号:US7803940B2
    公开(公告)日:2010-09-28
  • US7998968B2
    申请人:——
    公开号:US7998968B2
    公开(公告)日:2011-08-16
查看更多